ArticleInternational journal of women's health2026
Identification and Validation of a Four-Gene Signature as a Novel Potential Diagnostic Biomarker Panel for Endometriosis: Causal and Mechanistic Insights from Mendelian Randomization and Bioinformatics.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometriosis (EMS) is an estrogen-dependent disease that can lead to chronic pain and infertility. Small ubiquitin-related modifier (SUMO)ylation, a key post-translational modification, has been demonstrated to be associated with endometrial dysfunction, but its role in EMS remains unclear. This study aims to identify SUMOylation-related genes as potential biomarkers for EMS utilizing bioinformatics approaches. Methods: The GSE51981, GSE7305, and GSE214411 datasets and 194 SUMOylation-related genes were assessed. The differential expression analysis and weighted gene co-expression network analysis were performed to identify candidate genes associated with EMS and SUMOylation. Subsequently, the univariable and multivariable Mendelian randomization analyses were used to investigate causal relationships. The receiver operating characteristic curve and nomogram were constructed for assessing the performance of candidate genes. Furthermore, the biological roles of candidate biomarkers were evaluated through gene set enrichment analysis. Additionally, immune infiltration levels were analyzed and pseudo-time trajectory analysis was conducted to assess cell differentiation dynamics. Results: CRYZ, FRMD4B, FZD6, and TPST1 were identified as biomarkers associated with SUMOylation in EMS, all with area under the curve values above 0.75, suggesting good diagnostic performance. The constructed nomogram, which incorporated these biomarkers, demonstrated exceptional predictive capabilities for EMS risk. Furthermore, these biomarkers functioned through common enriched pathways, including the cell cycle, neuroactive ligand-receptor interaction, and ubiquitin-mediated proteolysis. Notably, immune cell analysis revealed significant infiltration of regulatory T cells and memory B cells in EMS. Pseudo-time trajectory analysis indicated that epithelial cells displayed distinct expression patterns for the biomarkers across five differentiation stages. Conclusion: This study identifies CRYZ, FRMD4B, FZD6, and TPST1 as potential diagnostic and therapeutic targets associated with SUMOylation in EMS. These findings provide potential clinical insights for the non-invasive detection and risk stratification of EMS, which might help improve the efficiency of early diagnosis and the development of personalized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.